Horizon Kinetics Asset Management LLC Has $1.87 Million Stock Position in Novo Nordisk A/S (NYSE:NVO)

Horizon Kinetics Asset Management LLC grew its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 1.6% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 15,718 shares of the company’s stock after buying an additional 250 shares during the quarter. Horizon Kinetics Asset Management LLC’s holdings in Novo Nordisk A/S were worth $1,872,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. Advisor OS LLC boosted its position in Novo Nordisk A/S by 0.6% during the 2nd quarter. Advisor OS LLC now owns 13,972 shares of the company’s stock worth $1,994,000 after buying an additional 82 shares during the period. Cascade Financial Partners LLC lifted its holdings in shares of Novo Nordisk A/S by 2.3% during the second quarter. Cascade Financial Partners LLC now owns 3,801 shares of the company’s stock worth $543,000 after purchasing an additional 84 shares during the period. Novare Capital Management LLC grew its stake in shares of Novo Nordisk A/S by 3.2% in the third quarter. Novare Capital Management LLC now owns 2,727 shares of the company’s stock worth $325,000 after purchasing an additional 85 shares during the last quarter. AA Financial Advisors LLC grew its stake in shares of Novo Nordisk A/S by 3.2% in the second quarter. AA Financial Advisors LLC now owns 2,805 shares of the company’s stock worth $400,000 after purchasing an additional 86 shares during the last quarter. Finally, Steel Grove Capital Advisors LLC increased its holdings in Novo Nordisk A/S by 2.3% in the second quarter. Steel Grove Capital Advisors LLC now owns 3,790 shares of the company’s stock valued at $541,000 after purchasing an additional 86 shares during the period. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have commented on NVO shares. StockNews.com raised Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Finally, BMO Capital Markets decreased their target price on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a research report on Thursday, October 17th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Novo Nordisk A/S currently has a consensus rating of “Buy” and an average target price of $144.50.

Novo Nordisk A/S Trading Down 0.5 %

NYSE NVO opened at $104.56 on Tuesday. The stock has a market capitalization of $469.22 billion, a P/E ratio of 33.84, a P/E/G ratio of 1.35 and a beta of 0.42. The business has a 50 day simple moving average of $114.83 and a 200 day simple moving average of $128.64. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. Novo Nordisk A/S has a one year low of $94.73 and a one year high of $148.15.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.